anti-cd19 cart

Anti-CD19 CAR-T cell therapy is a platform of adoptive cellular immunotherapy where a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) specific for the CD19 antigen. CD19 is a cell surface protein expressed throughout B-cell development, making it a highly effective target for B-cell malignancies and B-cell-mediated autoimmune diseases. The therapy typically involves leukapheresis, ex vivo genetic modification (often using lentiviral or retroviral vectors), expansion, and re-infusion into the patient following lymphodepleting chemotherapy. Several anti-CD19 CAR-T products are FDA-approved for hematological cancers, including tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), and lisocabtagene maraleucel (Breyanzi), for indications such as B-cell acute lymphoblastic leukemia (B-ALL) and various B-cell non-Hodgkin lymphomas. The platform is also being investigated for refractory autoimmune conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), where it aims to achieve deep B-cell depletion to reset the immune system. Clinical trials for RA (e.g., SWK002) and SLE (e.g., CABA-201) have shown promising early results in achieving drug-free remission.

Other names

anti-CD19 CAR-Tanti-CD-19 CAR-Tanti-CD 19 CAR-TCART19CART-19CART 19CD19 CAR-TCD-19 CAR-TCD 19 CAR-Tanti-CD19 chimeric antigen receptor T-cell therapyanti-CD-19 chimeric antigen receptor T-cell therapyanti-CD 19 chimeric antigen receptor T-cell therapy